# PT-141 Nasal Spray vs Injection: Compared **By TelosRX Editorial Team** ยท 2026-08-14 **PT-141 nasal spray and PT-141 injection are not equivalent. An intranasal bremelanotide formulation was studied early on but never carried through to FDA approval, largely because of blood pressure findings tied to that route. [Subcutaneous PT-141](https://www.telosrx.com/pages/pt-141) is the format the pivotal trials used.** People search for a **pt-141 peptide nasal spray** because a spray sounds easier than a needle, and because nasal delivery is a legitimate route for plenty of other drugs. This peptide went a different way, and the reason is worth knowing before you pick a format. Here is what happened, how the two routes differ on absorption and dose control, and where the evidence sits today. ## Intranasal Bremelanotide Was Real, and It Came First PT-141 is the research name for bremelanotide, a melanocortin receptor agonist that acts at MC3R and MC4R receptors in the hypothalamus. It works centrally, in the brain, rather than by changing blood flow, which is covered in more depth in our guide to [what PT-141 is and how bremelanotide works](https://www.telosrx.com/blogs/peptides/what-is-pt-141-bremelanotide-guide). Early clinical development used an intranasal spray. That formulation was studied in men with erectile dysfunction, and phase 2 work showed a dose-dependent erectile response, with effects reported in roughly the 30 to 60 minute range. **So the nasal spray was not a fringe idea.** It was the original delivery method, and it produced a signal. What ended it was the route, not the molecule. ## Why Development Moved to Subcutaneous Injection The deciding issue was how much drug actually reached circulation, and how consistently. Published work in the _Journal of Hypertension_ describes the intranasal route as carrying [wide variability in bioavailability](https://pmc.ncbi.nlm.nih.gov/articles/PMC5338879/), which could expose some people to levels above what efficacy required and raise the risk of autonomic effects including elevations in blood pressure. Subcutaneous dosing was expected to produce a tighter relationship between the dose given and the exposure achieved, which is what makes it possible to identify a dosing schedule that is both effective and safety-characterised. The story compresses to one line. For a compound with a known blood pressure signal, an unpredictable absorbed dose is a safety variable rather than a convenience trade-off. That is why the subcutaneous route went the distance. ## PT-141 Nasal Spray vs Injection: Head-to-Head Factor Intranasal bremelanotide (nasal spray) Subcutaneous bremelanotide (PT-141 injection) **Development status** Studied in earlier development, not advanced to FDA approval Carried through phase 3 and approved as Vyleesi in 2019 **Absorption** Wide variability in bioavailability across individuals and doses Tighter, more predictable relationship between dose and exposure **Dose control** Absorbed amount is harder to pin down, so exposure can overshoot Measured dose delivered into subcutaneous tissue **Blood pressure considerations** Variable exposure was linked to heightened risk of blood pressure elevation with this route Small, transient blood pressure increases with a modest heart rate decrease at studied doses **Pivotal efficacy evidence** No phase 3 approval package RECONNECT: two randomized, double-blind, placebo-controlled trials **FDA-approved product** None Vyleesi, 1.75 mg autoinjector, for acquired generalized HSDD in premenopausal women **Onset used in studies** Effects reported around 30 to 60 minutes in phase 2 male work Label specifies administration at least 45 minutes before anticipated sexual activity **Available through Telos Rx** No Yes, as a compounded subcutaneous preparation, subject to medical approval by a licensed provider The short version: the injection is the format with the trial evidence behind it. See how Telos Rx supplies compounded PT-141 and what a provider review involves. [See PT-141 at Telos Rx](https://www.telosrx.com/pages/pt-141) ## The Evidence Base Sits Almost Entirely on the Injection The phase 3 program for bremelanotide is the RECONNECT trials, two randomized, double-blind, placebo-controlled studies in premenopausal women with acquired, generalized hypoactive sexual desire disorder. The co-primary endpoints covered desire and the distress associated with low desire, and the [published RECONNECT data](https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/) supported the 2019 approval. Every one of those participants received the drug subcutaneously. **When someone cites trial evidence for bremelanotide, they are citing evidence generated with an injection.** For the female-specific picture, see our breakdown of [PT-141 for women, HSDD and Vyleesi](https://www.telosrx.com/blogs/peptides/pt-141-for-women-hsdd-guide). For the off-label male research, see [what the research shows in men](https://www.telosrx.com/blogs/peptides/pt-141-for-men-research-guide). ## Regulatory Status, Route by Route Vyleesi is a 1.75 mg subcutaneous autoinjector, and the [NIH LiverTox record](https://www.ncbi.nlm.nih.gov/books/NBK573221/) confirms the 2019 US approval and the subcutaneous route. Label parameters specify administration at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours, and no more than eight doses per month. Those are label figures, not instructions to any reader. There is no FDA-approved intranasal bremelanotide product. Separately, **compounded PT-141 is not FDA-approved either**. It is prepared by licensed US compounding pharmacies under federal compounding regulations, and it requires a prescription and provider oversight. HSDD in premenopausal women is the only FDA-approved indication for bremelanotide in any form. Use in men is off-label. ## Side Effects Were Characterised With the Injection Too In the trials, nausea was the most common adverse effect at roughly 40 percent of participants and was usually transient. Flushing, headache and injection-site reactions were also reported, along with transient increases in blood pressure paired with a modest decrease in heart rate. Focal hyperpigmentation has been reported with repeated dosing. Trials excluded people with uncontrolled hypertension or known cardiovascular disease, and Vyleesi is not for those groups. Our write-up of [what the trials reported on side effects](https://www.telosrx.com/blogs/peptides/pt-141-side-effects-safety) covers this in detail. ## If You Are Weighing a Nasal Spray Nasal preparations of various peptides are sold, and this article makes no claim about any specific seller or product. The factual points are simple enough to hold in your head. - No intranasal bremelanotide product holds FDA approval. - The efficacy and safety dataset people cite for bremelanotide was generated subcutaneously. - The published concern with the nasal route was variable absorption, and the consequence of variable absorption is a less predictable dose. - Any route, including the injection, should be discussed with a licensed provider who knows your blood pressure and cardiovascular history. That last point carries the most weight. A centrally acting melanocortin agonist is not a supplement, and route selection is a clinical decision rather than a preference. ## How Telos Rx Supplies PT-141 Telos Rx offers compounded PT-141 as an **as-needed subcutaneous dose**, taken ahead of anticipated intimacy. That is the route the RECONNECT trials used and the route the approved product uses, which is why it is the format we carry. Everything runs through an online-first, asynchronous telehealth process. You complete an intake, and any prescription is subject to medical approval by a licensed provider. Approval is not guaranteed. Compounded PT-141 is not FDA-approved, availability covers all 50 states, and formulations may vary by state. Our [PT-141 dosage guide](https://www.telosrx.com/blogs/peptides/pt-141-dosage-guide) reports what the research and label specify. If you are comparing PT-141 with more familiar options, see [how it differs from Viagra and Cialis](https://www.telosrx.com/blogs/peptides/pt-141-vs-viagra-cialis), plus our summary of the [research-backed benefits of PT-141](https://www.telosrx.com/blogs/peptides/pt-141-bremelanotide-benefits-research-guide). ## Frequently Asked Questions ### Is there an FDA-approved PT-141 nasal spray? No. There is no FDA-approved intranasal bremelanotide product. The only FDA-approved bremelanotide product is Vyleesi, a 1.75 mg subcutaneous autoinjector approved in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded PT-141, in any format, is also not FDA-approved and is prepared by licensed US compounding pharmacies under federal compounding regulations. ### Why was bremelanotide nasal spray not approved? The intranasal route was associated with wide variability in bioavailability, meaning the absorbed dose was harder to predict. Published work notes this could expose some people to levels above those needed for effect and raise the risk of autonomic effects including blood pressure elevation. Development moved to subcutaneous dosing, which gives a tighter relationship between dose and exposure. ### Does PT-141 nasal spray work as well as the injection? There is no head-to-head approval-grade comparison to answer that cleanly. What can be said is that the phase 3 evidence base, the RECONNECT trials, used subcutaneous dosing, and the approved product is subcutaneous. Earlier intranasal phase 2 work in men did show a dose-dependent response, but that route was not advanced through to approval. ### Is the PT-141 injection difficult to use? Vyleesi is supplied as a subcutaneous autoinjector, the same general route used for many at-home injectable medicines. Injection-site reactions were among the adverse effects reported in trials, along with nausea, flushing and headache. How any compounded preparation is supplied and administered is determined by the prescribing provider, not chosen by the patient. ### Can men use PT-141, and does the route matter for men? Use in men is off-label, since the only FDA-approved indication is HSDD in premenopausal women. Phase 2 work in men with erectile dysfunction used the intranasal formulation and showed a dose-dependent erectile response, with effects reported around 30 to 60 minutes. That route was not advanced to approval, and current compounding practice uses the subcutaneous form. ### Is compounded PT-141 the same as Vyleesi? PT-141 and bremelanotide are the same molecule, so the active ingredient matches. Vyleesi is the FDA-approved branded autoinjector for premenopausal women with HSDD. Compounded PT-141 is not FDA-approved, is prepared by licensed US compounding pharmacies under federal compounding regulations, and requires a prescription plus review by a licensed provider. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ Want the route with the trial evidence behind it? See [compounded PT-141 at Telos Rx](https://www.telosrx.com/pages/pt-141), then start a private, asynchronous online visit: [online visit for men](https://start.telosrx.com/start-online-visit/pt141men) or [online visit for women](https://start.telosrx.com/start-online-visit/pt141women). A licensed provider reviews every intake, and approval is not guaranteed. **Tags:** bremelanotide, HSDD, nasal spray, peptides, PT-141, sexual health, subcutaneous injection, Vyleesi --- > Source: [Telos RX](https://www.telosrx.com/blogs/peptides/pt-141-nasal-spray-vs-injection)